Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1871392 | 0.93 | CYP3A4 (0.40) | CYP3A4TSHRMAPK1ALDH1A1 | |
| SCHEMBL10718639 | 0.92 | CYP3A4 (0.33) | CYP3A4TSHRMAPK1ALDH1A1TP53 | |
| SCHEMBL5872014 | 0.76 | PGK1 (0.31) | MAPK1 | |
| SCHEMBL23069369 | 0.75 | CYP3A4 (0.36) | CYP3A4TSHRMAPK1ALDH1A1TP53 | |
| SCHEMBL10823047 | 0.75 | DAO (0.34) | — | |
| SCHEMBL11148284 | 0.73 | ACHE (0.42) | CYP3A4TSHRALDH1A1TDP1CA1 | |
| SCHEMBL8109982 | 0.71 | TSHR (0.57) | CYP3A4TSHRMAPK1ALDH1A1TP53 | |
| SCHEMBL39444 | 0.71 | TSHR (0.57) | CYP3A4TSHRMAPK1ALDH1A1TP53 | |
| SCHEMBL6735607 | 0.71 | TAAR1 (0.45) | ALDH1A1 | |
| SCHEMBL10422356 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240713-A1 | AROMATIC AND HETEROAROMATIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240713-A1 | AROMATIC AND HETEROAROMATIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | SLC40A1, PAH, FECH | CYP3A4 108/4885TSHR 623/4885MAPK1 3743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.